Success Metrics

Active Trials
1(33%)

Phase Distribution

Ph phase_4
3
100%

Phase Distribution

0

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution3 total trials
Phase 4Post-market surveillance
3(100.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Terminated(1)
Other(1)

Detailed Status

unknown1
Recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 43 (100.0%)

Trials by Status

unknown133%
recruiting133%
withdrawn133%

Recent Activity

1 active trials
Showing 3 of 3
recruitingphase_4

Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease

NCT06964269
unknownphase_4

A Study of Acthar Gel Alone or With Tacrolimus to Reduce Proteinuria in Fibrillary Glomerulopathy Patients

NCT05546047
withdrawnphase_4

ACTHAR Gel for Drug REsistant Nephrotic Syndrome in Children

NCT03408405

Clinical Trials (3)

Showing 3 of 3 trials
NCT06964269Phase 4

Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease

Recruiting
NCT05546047Phase 4

A Study of Acthar Gel Alone or With Tacrolimus to Reduce Proteinuria in Fibrillary Glomerulopathy Patients

Unknown
NCT03408405Phase 4

ACTHAR Gel for Drug REsistant Nephrotic Syndrome in Children

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3